Abstract
The immunosuppressive drugs Cyclosporine A (CSA) and prednisolone are widely used to prevent graftversus- host-disease (GVHD) after allogenetic stem cell transplantation (allo-SCT). However, it remains to be elucidated whether these drugs have an effect on the balance of effector cells and CD4+CD25+ regulatory T cells (Tregs) which determines the development of stable allograft tolerance. In the current study, we found that proliferation, activation and function of T cells especially for virus-specific CD8+ T cells and Tregs were inhibited by CSA and prednisolone in a dosedependent manner. These effects were associated with lower secretion of cytokines and arresting T cells in the G0/G1 phase of cell cycle. Moreover, CSA and prednisolone could reduce the expression of FOXP3 and suppressive function of Tregs. Our data indicated that CSA and prednisolone impaired the development and function of CD8+ T cells as well as Tregs in a similar way suggesting that CSA and prednisolone might increase the susceptibility to develop viral diseases and block the potential induction of immune tolerance in clinical settings.
Keywords: T cells, cyclosporine A, prednisolone
Current Signal Transduction Therapy
Title: The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells
Volume: 4 Issue: 3
Author(s): Fei Fei, Yingzhe Yu, Anita Schmitt, Markus Thomas Rojewski, Baoan Chen, Marlies Gotz, Philippe Guillaume, Donald Bunjes and Michael Schmitt
Affiliation:
Keywords: T cells, cyclosporine A, prednisolone
Abstract: The immunosuppressive drugs Cyclosporine A (CSA) and prednisolone are widely used to prevent graftversus- host-disease (GVHD) after allogenetic stem cell transplantation (allo-SCT). However, it remains to be elucidated whether these drugs have an effect on the balance of effector cells and CD4+CD25+ regulatory T cells (Tregs) which determines the development of stable allograft tolerance. In the current study, we found that proliferation, activation and function of T cells especially for virus-specific CD8+ T cells and Tregs were inhibited by CSA and prednisolone in a dosedependent manner. These effects were associated with lower secretion of cytokines and arresting T cells in the G0/G1 phase of cell cycle. Moreover, CSA and prednisolone could reduce the expression of FOXP3 and suppressive function of Tregs. Our data indicated that CSA and prednisolone impaired the development and function of CD8+ T cells as well as Tregs in a similar way suggesting that CSA and prednisolone might increase the susceptibility to develop viral diseases and block the potential induction of immune tolerance in clinical settings.
Export Options
About this article
Cite this article as:
Fei Fei, Yu Yingzhe, Schmitt Anita, Rojewski Thomas Markus, Chen Baoan, Gotz Marlies, Guillaume Philippe, Bunjes Donald and Schmitt Michael, The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells, Current Signal Transduction Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157436209789057502
DOI https://dx.doi.org/10.2174/157436209789057502 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Stem Cells and Tissue Regeneration (Executive Guest Editor: Roberta Di Pietro)]
Current Pharmaceutical Design Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation
Current Medicinal Chemistry Neutrophil MiRNA-128-3p is Decreased During Active Phase of Granulomatosis with Polyangiitis
Current Genomics Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Current Medicinal Chemistry An Overview on 2-arylquinolin-4(1H)-ones and Related Structures as Tubulin Polymerisation Inhibitors
Current Topics in Medicinal Chemistry Molecular Chaperone Hsp90 as a Target for Oxidant-Based Anticancer Therapies
Current Medicinal Chemistry Induced Stem Cells as a Novel Multiple Sclerosis Therapy
Current Stem Cell Research & Therapy Topoisomerase I and II Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models
Current Cancer Drug Targets Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery Aging and Inflammation: Etiological Culprits of Cancer
Current Aging Science 9-Hydroxyellipticine and Derivatives as Chemotherapy Agents
Mini-Reviews in Medicinal Chemistry Prophylaxis of Cancer
Current Cancer Therapy Reviews